David Cosgrove
Overview
Explore the profile of David Cosgrove including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, et al.
Future Oncol
. 2024 Jun;
20(30):2241-2248.
PMID: 38861293
Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in...
2.
Fakih M, Raghav K, Chang D, Larson T, Cohn A, Huyck T, et al.
EClinicalMedicine
. 2023 Apr;
58:101917.
PMID: 37090438
Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with...
3.
Ronot M, Ferraioli G, Muller H, Friedrich-Rust M, Filice C, Vilgrain V, et al.
Eur Radiol
. 2020 Sep;
31(3):1578-1587.
PMID: 32902745
Objectives: To compare liver stiffness measurement (LSM) provided by Canon 2D-shear wave elastography (2D-SWE) and transient elastography (TE), the latter being the reference method. Methods: Prospective study conducted in four...
4.
McNamara M, Goyal L, Doherty M, Springfeld C, Cosgrove D, Sjoquist K, et al.
Future Oncol
. 2020 May;
16(16):1069-1081.
PMID: 32374623
Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated...
5.
Chauhan N, Mulcahy M, Salem R, Benson Iii A, Boucher E, Bukovcan J, et al.
JMIR Res Protoc
. 2019 Jan;
8(1):e11545.
PMID: 30664496
Background: Colorectal cancer is one of the most common cancers and causes of cancer-related death. Up to approximately 70% of patients with metastatic colorectal cancer (mCRC) have metastases to the...
6.
Dietrich C, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, et al.
Ultraschall Med
. 2018 Sep;
38(4):e48.
PMID: 30176678
No abstract available.
7.
Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, et al.
JMIR Res Protoc
. 2018 Aug;
7(8):e11234.
PMID: 30111528
Background: Globally, hepatocellular carcinoma is the second most common cause of cancer deaths. It remains challenging to intensify cancer treatment without impairing liver function. Objective: The objective of the TheraSphere...
8.
Sidhu P, Cantisani V, Dietrich C, Gilja O, Saftoiu A, Bartels E, et al.
Ultraschall Med
. 2018 Mar;
39(2):154-180.
PMID: 29510440
The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS) deals with the use of microbubble ultrasound contrast outside the liver in the many established...
9.
Sidhu P, Cantisani V, Dietrich C, Gilja O, Saftoiu A, Bartels E, et al.
Ultraschall Med
. 2018 Mar;
39(2):e2-e44.
PMID: 29510439
The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS) deals with the use of microbubble ultrasound contrast outside the liver in the many established...
10.
Dietrich C, Averkiou M, Nielsen M, Barr R, Burns P, Calliada F, et al.
Ultrasound Int Open
. 2018 Feb;
4(1):E2-E15.
PMID: 29423461
"How to perform contrast-enhanced ultrasound (CEUS)" provides general advice on the use of ultrasound contrast agents (UCAs) for clinical decision-making and reviews technical parameters for optimal CEUS performance. CEUS techniques...